Current approaches to the treatment of frequently recurrent urticaria.

Автор(и)

DOI:

https://doi.org/10.26641/2307-0404.2019.4.189327

Ключові слова:

chronic urticaria, immunoglobulins E, omalizumab

Анотація

The article presents summarized materials on etiology, pathogenesis, classification, clinical manifestations and treatment of chronic urticuria, The management of patients with this pathology at Dniprovsky Allergological Center was analyzed. For assessment of quality of life SKINDEX-29 questionnaire was used. The questionnaire includes three sections: symptoms, emotions and functions. Physical symptoms include six points: tenderness, heartburn or tingling, itching unpleasant sensations when cotacting with water, skin irritation, sensitivity. The emotional sphere is characterized by such ten points as: concern about the condition of the skin; deppression; feeling of shame; concern that scars can remain after skin disease; feelings about worsening of the skin; anxious mood; embarrassment, feeling of humiliation; skin irritation; rejection of oneself. “Features” section has twelve items: sleep quality; work and hobbies; social activity; sex life; solitude; fatigue; unwillingness to leave home; limiting intimacy with others; complexity in carrying out daily activities; difficulty in expressing feelings; obstruction to create relationships with others; limiting close communication with relatives. Gastrointestinal system was also examined: fibrogastroduodenoscopy with determination of Helicobacter Pylori, ultrasound diagnosis of abdominal organs, the intensity of clinical symptoms was determined on a UAS7 scale. Fifteen patients (including eight women and seven men) were successfully treated with omalizumab. The mean age was 39.1 ± 3.6 years. The average duration of the disease in patients was 5.1 ± 0.9 years. The intensity of symptoms was determined before treatment after the first and second injection of Omalizumab. After the first injection, there was a positive trend. The clinical effect occurred in seventy-two hours. Statistical processing of the study results was performed using Statistica v.6.1® software. (StatSoft, USA). The inclusion of omalizumab is an effective treatment for chronic urticaria in the absence of an effect from antihistamines.

Біографії авторів

E. M. Dytyatkovska

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Occupational Diseases and Clinical Immunology
Blyzhnia str., 31, Dnіprо, 49102, Ukraine

MI «Dnipro Clinical Association of Emergency Medicine» DCC
Allergy Department
Schmidta str., 26, Dnipro, 49000, Ukraine

Yu. V. Bendetska

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Occupational Diseases and Clinical Immunology
Blyzhnia str., 31, Dnіprо, 49102, Ukraine

MI «Dnipro Clinical Association of Emergency Medicine» DCC
Allergy Department
Schmidta str., 26, Dnipro, 49000, Ukraine

I. A. Rodkina

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Occupational Diseases and Clinical Immunology
Blyzhnia str., 31, Dnіprо, 49102, Ukraine

MI «Dnipro Clinical Association of Emergency Medicine» DCC
Allergy Department
Schmidta str., 26, Dnipro, 49000, Ukraine

N. А. Nedogibchenko

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Occupational Diseases and Clinical Immunology
Blyzhnia str., 31, Dnіprо, 49102, Ukraine

MI «Dnipro Clinical Association of Emergency Medicine» DCC
Allergy Department
Schmidta str., 26, Dnipro, 49000, Ukraine

Посилання

Antomonov MYu. [Mathematical processing and analysis of biomedical data]. Kyiv: Medinform. 2018;579. Russian.

Cezmi AA, Agache I, Abdel-Gadir A. [Global atlas of allergy]. European Academy of Allergy and Clinical Immunology. 2014;206-11.

Sussman G, Hébert J, Gulliver W. [Omalizumab Retreatment of Patients swith Chronic Idopathic Urti­caria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study]. SKIN The Journal of Cutaneous Medicine. 2017;1(3.1):127. doi: https://doi.org/10.25251/skin.1.supp.126

Metz M, Ohanyan T, Church MK. [Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria]. JAMA Dermato­logy. 2014;150(3):288-90. doi: https://doi.org/10.1001/jamadermatol.2013.8705

Zuberbier T, Aberer W, Asero R. [The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update]. Allergy. 2018;73:1393-414.

Zuberbier T, Aberer W, Asero R. [The EAACI/­GA2LEN/EDF/WAO urticaria guideline for the defini­tion, classification, diagnosis, and management of urti­caria: the 2013 revision and update]. Allergy. 2014;69:868-87. doi: https://doi.org/10.1111/all.12313

Maurer M, Kaplan A, Rosén K. [The XTEND-CIU study: Long-term use of omalizumab in chronic idio­pathic urticaria]. Journal of Allergy and Clinical Immu­no­logy. 2018;141:1138-9. doi: https://doi.org/10.1016/j.jaci.2017.10.018

Türk M, Yılmaz İ, Bahçecioğlu SN. [Treatment and retreatment with omalizumab in chronic spon­taneous urticaria: Real life experience with twenty-five patients]. Allergology International. 2018;67(1):85-89. doi: https://doi.org/10.1016/j.alit.2017.05.003

##submission.downloads##

Як цитувати

1.
Dytyatkovska EM, Bendetska YV, Rodkina IA, Nedogibchenko NА. Current approaches to the treatment of frequently recurrent urticaria. Med. perspekt. [інтернет]. 26, Грудень 2019 [цит. за 23, Грудень 2024];24(4):89-93. доступний у: https://journals.uran.ua/index.php/2307-0404/article/view/189327

Номер

Розділ

КЛІНІЧНА МЕДИЦИНА